

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20812

ADMINISTRATIVE DOCUMENTS

American Home Products Corporation
Madison, New Jersey

Supplement to NDA 20-589
Pediatric Advil® Drops
(ibuprofen, 100mg/2.5mL)

ITEM 13: PATENT INFORMATION

- | | |
|---|------------------------------------|
| 1. Active Ingredient (s): | Ibuprofen |
| 2. Strength(s): | 100mg/2.5mL |
| 3. Trade Name: | Pediatric Advil® (ibuprofen) Drops |
| 4. Dosage Form, Route of Administration: | Concentrated Suspension, Oral |
| 5. Applicant Firm Name: | Whitehall-Robins Healthcare |
| 6. NDA Number: | 20-589 |
| 7. Approval Date of Original Application: | June 27, 1996 |
| 8. Exclusivity For Pediatric Advil Drops: | Not applicable |

**APPEARS THIS WAY
ON ORIGINAL**

**APPEARS THIS WAY
ON ORIGINAL**

EXCLUSIVITY SUMMARY for NDA # 20-812 SUPPL # _____

Trade Name Adult Drops 100mg/25mL Generic Name Ibuprofen Suspension

Applicant Name Whitehall-Robins Healthcare HFD-550

Approval Date, if known _____

PART I IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, but only for certain supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following question about the submission.

a) Is it an original NDA?
YES // NO /___/

b) Is it an effectiveness supplement?
YES /___/ NO //

If yes, what type? (SE1, SE2, etc.) _____

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.")
YES /___/ NO //

If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

A bioequivalence study was conducted with
children's Advil Suspension

If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

d) Did the applicant request exclusivity?

YES // NO /___/

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

applicant requested exclusivity based upon that exclusivity provided to Children's Adult Suspension.

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. Has a product with the same active ingredient(s), dosage form, strength, route of administration, and dosing schedule, previously been approved by FDA for the same use? (Rx-to-OTC switches should be answered NO-please indicate as such.)

YES // NO /___/

If yes, NDA # 20-603 Drug Name Modrin Drops

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

3. Is this drug product or indication a DESI upgrade?

YES /___/ NO /___/

IF THE ANSWER TO QUESTION 3 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES

(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES /___/ NO /___/

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA# _____
NDA# _____
NDA# _____

2. Combination product.

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES /___/ NO /___/

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA# _____
NDA# _____
NDA# _____

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. IF "YES" GO TO PART III.

PART III THREE-YEAR EXCLUSIVITY FOR NDA'S AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of summary for that investigation.

YES /___/ NO /___/

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

- (a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES /___/ NO /___/

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

YES /___/ NO /___/

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES /___/ NO /___/

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES /___/ NO /___/

If yes, explain: _____

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES /___/ NO /___/

If yes, explain: _____

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

- a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1 YES /___/ NO /___/

Investigation #2 YES /___/ NO /___/

- If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

- b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1 YES /___/ NO /___/

Investigation #2 YES /___/ NO /___/

- If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

- c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

Investigation #1	!	
IND # _____ YES /___/	!	NO /___/ Explain: _____
	!	_____
Investigation #2	!	
IND # _____ YES /___/	!	NO /___/ Explain: _____
	!	_____

(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1	!	
YES /___/ Explain _____	!	NO /___/ Explain _____
_____	!	_____
_____	!	_____
Investigation #2	!	
YES /___/ Explain _____	!	NO /___/ Explain _____
_____	!	_____
_____	!	_____

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

YES /___/ NO /___/

If yes, explain: _____

Samalia D. Cook
Signature
Title: Consumer Safety Officer

1/20/98
Date

M. W. [unclear] 1/20/98
Signature of Division Director

Date

cc: Original NDA

Division File

HFD-93 Mary Ann Holovac

PEDIATRIC PAGE

(Complete for all original applications and all efficacy supplements)

NDA/PLA # 20-812 Supplement # _____ Circle one: SE1 SE2 SE3 SE4 SE5 SE6

HFD-550 Trade (generic) name/dosage form: Pediatric Adult Drops Action: AP AE NA
(Croup/bronchitis suspension), 100mg/2.5mL

Applicant Wichita-Robins Healthcare Therapeutic Class Pain reliever/Fever Reducer

Indication(s) previously approved N/A
Pediatric labeling of approved indication(s) is adequate _____ inadequate _____

Indication in this application For long term relief of the pain of minor aches and pains caused by colds, flu, sore throats, headaches, and toothaches.
(For supplements, answer the following questions in relation to the proposed indication.)

- 1. **PEDIATRIC LABELING IS ADEQUATE.** Appropriate information has been submitted in this or previous applications and has been adequately summarized in the labeling to permit satisfactory labeling for all pediatric subgroups. Further information is not required.
- 2. **PEDIATRIC STUDIES ARE NEEDED.** There is potential for use in children, and further information is required to permit adequate labeling for this use.
 - a. A new dosing formation is needed, and applicant has agreed to provide the appropriate formulation.
 - b. The applicant has committed to doing such studies as will be required.
 - (1) Studies are ongoing,
 - (2) Protocols were submitted and approved.
 - (3) Protocols were submitted and are under review.
 - (4) If no protocol has been submitted, explain the status of discussions on the back of this form.
 - c. If the sponsor is not willing to do pediatric studies, attach copies of FDA's written request that such studies be done and of the sponsor's written response to that request.
- 3. **PEDIATRIC STUDIES ARE NOT NEEDED.** The drug/biologic product has little potential for use in children. Explain, on the back of this form, why pediatric studies are not needed.
- 4. **EXPLAIN.** If none of the above apply, explain, as necessary, on the back of this form.

EXPLAIN, AS NECESSARY, ANY OF THE FOREGOING ITEMS ON THE BACK OF THIS FORM.

Sandra P. Cook Signature of Preparer and Title (PM, MO, other) _____ Date 4/30/97

cc: Orig NDA/PLA # 20-812
HFD-550 /Div. File
NDA/PLA Action Package
HFD-510/GTroendle (plus, for CDER APs and AEs, copy of action letter and labeling)
HFD-560

E: A new Pediatric Page must be completed at the time of each action even though one was prepared at the time of the last action.


BEST POSSIBLE COPY

Debarment Statement

Whitehall-Robins, to the best of its knowledge, did not and will not use in any capacity the services of any person debarred under sections 306 of the act in connection with such application.

**APPEARS THIS WAY
ON ORIGINAL**

**APPEARS THIS WAY
ON ORIGINAL**



**Rich Cuprys
Assistant Vice-President,
Regulatory Affairs
Whitehall-Robins Healthcare**

REQUEST FOR TRADEMARK REVIEW

To: Labeling and Nomenclature Committee
Attention: Mr. Don Boring, Chair

From: Anti-inflammatory, Analgesic, and Ophthalmic Drug Product, HFD-550
Attention: Bart Ho Phone: 827-2502

Date: January 31, 1997

NDA #: 20-812

Company Name: American Home Product (Whitehall-Robins Healthcare)

Subject: Request the review of trade name for NDA 20-812

Descriptive:

Currently Proposed Trademark:

NDA:	20-812
Trade Mark:	Pediatric Advil Drops
Dosage form and strength:	Ibuprofen Oral Suspensions, 40 mg/mL
Indications for Use:	Recommended for children 2 to 3 years old

Established name, including dosage form: Ibuprofen Oral Suspensions

Other trademarks by the same firm for companion products:

Trademark of previously approved drug product:

NDA:	20-589
Trade Mark:	Children's Advil
Dosage form and strength:	Ibuprofen Oral Suspensions, 20 mg/mL
Indications for Use:	This product is recommended for children 2 to 12 years old

Note: The name of the drug product was initially named as "Children's Advil Ibuprofen Suspension Liquid". We request the name be changed to "Children's Advil Ibuprofen Oral Suspension".

Consult #762 (HFD-550)

PEDIATRIC ADVIL DROPS

ibuprofen oral suspension

There were no look-alike/sound-alike conflicts or misleading aspects found in the proposed proprietary name.

The Committee has no reason to find the proposed proprietary name unacceptable.

D. Berling 3/27/97, Chair
CDER Labeling and Nomenclature Committee

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL